Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 4/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343792 | 0.90 | DHODH (0.42) | SCN9ADHODHMRGPRX4 | |
| SCHEMBL3342056 | 0.89 | NPC1 (0.41) | SCN9ADHODHNPC1KDM4EALDH1A1 | |
| SCHEMBL3343333 | 0.89 | SCN9A (0.41) | SCN9ANPSR1NPC1TGFBR1KDM4E | |
| SCHEMBL3341965 | 0.85 | MAPK8 (0.43) | SCN9ADHODHMRGPRX4NPC1KDM4E | |
| SCHEMBL3341989 | 0.82 | TGFBR1 (0.41) | SCN9AMAPTDHODHMRGPRX4NPC1 | |
| SCHEMBL3341278 | 0.81 | SCN9A (0.43) | SCN9ANPC1ATMCYP46A1 | |
| SCHEMBL3347867 | 0.80 | NPC1 (0.42) | SCN9ADHODHNPC1KDM4E | |
| SCHEMBL3343592 | 0.77 | KMO (0.46) | SCN9AHTTDHODHNPC1ALDH1A1 | |
| SCHEMBL3342486 | 0.77 | DHODH (0.42) | SCN9ADHODHMRGPRX4NPC1KDM4E | |
| SCHEMBL3342567 | 0.76 | ALPL (0.46) | SCN9AMAPTDHODHTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2010-06-24 | — | — | US | disclosed |
| WO-2008031500-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160386-A1 | 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS | PPARA, PPARD, PPARG | SCN9A 2847/4885HSP90AA1 1632/4885MAPT 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.